Kalpit Patel
Stock Analyst at B. Riley Securities
(1.28)
# 3,303
Out of 4,820 analysts
53
Total ratings
35%
Success rate
-10.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kalpit Patel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVBP ArriVent BioPharma | Initiates: Buy | $37 | $20.74 | +78.40% | 1 | Mar 20, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $20 → $24 | $19.27 | +24.58% | 6 | Mar 5, 2025 | |
| GERN Geron | Maintains: Buy | $5.5 → $3.5 | $1.42 | +146.48% | 3 | Feb 18, 2025 | |
| VSTM Verastem | Maintains: Buy | $7 → $9 | $7.49 | +20.16% | 4 | Jan 31, 2025 | |
| FHTX Foghorn Therapeutics | Initiates: Buy | $10 | $4.37 | +128.83% | 1 | Jan 30, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Neutral | $28 → $17 | $8.36 | +103.35% | 6 | Dec 13, 2024 | |
| PDSB PDS Biotechnology | Maintains: Buy | $9 → $7 | $1.26 | +455.56% | 5 | Nov 25, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $85 → $40 | $8.00 | +400.00% | 2 | Sep 20, 2024 | |
| KYMR Kymera Therapeutics | Maintains: Neutral | $31 → $36 | $33.30 | +8.12% | 2 | Jul 9, 2024 | |
| OVID Ovid Therapeutics | Maintains: Buy | $9 → $3 | $0.35 | +761.57% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $20 | $13.49 | +48.26% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 → $1 | $0.19 | +426.32% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $6 | $7.45 | -19.46% | 5 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $36 | $13.32 | +170.27% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $9 → $3 | $0.18 | +1,535.77% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $18 | $1.55 | +1,061.29% | 2 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $2.41 | +107.47% | 2 | Jul 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $100 | $7.50 | +1,233.33% | 1 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 | $6.51 | +1,052.07% | 2 | Sep 3, 2021 |
ArriVent BioPharma
Mar 20, 2025
Initiates: Buy
Price Target: $37
Current: $20.74
Upside: +78.40%
Rigel Pharmaceuticals
Mar 5, 2025
Maintains: Neutral
Price Target: $20 → $24
Current: $19.27
Upside: +24.58%
Geron
Feb 18, 2025
Maintains: Buy
Price Target: $5.5 → $3.5
Current: $1.42
Upside: +146.48%
Verastem
Jan 31, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $7.49
Upside: +20.16%
Foghorn Therapeutics
Jan 30, 2025
Initiates: Buy
Price Target: $10
Current: $4.37
Upside: +128.83%
Bicycle Therapeutics
Dec 13, 2024
Maintains: Neutral
Price Target: $28 → $17
Current: $8.36
Upside: +103.35%
PDS Biotechnology
Nov 25, 2024
Maintains: Buy
Price Target: $9 → $7
Current: $1.26
Upside: +455.56%
Corbus Pharmaceuticals Holdings
Sep 20, 2024
Maintains: Buy
Price Target: $85 → $40
Current: $8.00
Upside: +400.00%
Kymera Therapeutics
Jul 9, 2024
Maintains: Neutral
Price Target: $31 → $36
Current: $33.30
Upside: +8.12%
Ovid Therapeutics
Jun 18, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $0.35
Upside: +761.57%
May 9, 2024
Downgrades: Neutral
Price Target: $25 → $20
Current: $13.49
Upside: +48.26%
Dec 12, 2023
Downgrades: Neutral
Price Target: $3 → $1
Current: $0.19
Upside: +426.32%
Sep 7, 2023
Reiterates: Buy
Price Target: $6
Current: $7.45
Upside: -19.46%
Jul 25, 2023
Maintains: Buy
Price Target: $34 → $36
Current: $13.32
Upside: +170.27%
Nov 11, 2022
Downgrades: Neutral
Price Target: $9 → $3
Current: $0.18
Upside: +1,535.77%
Sep 22, 2022
Maintains: Buy
Price Target: $21 → $18
Current: $1.55
Upside: +1,061.29%
Jul 19, 2022
Maintains: Buy
Price Target: $6 → $5
Current: $2.41
Upside: +107.47%
Jan 24, 2022
Maintains: Buy
Price Target: $240 → $100
Current: $7.50
Upside: +1,233.33%
Sep 3, 2021
Downgrades: Neutral
Price Target: $75
Current: $6.51
Upside: +1,052.07%